ALTSTATION.IO

Cardinal Health, Inc. (CAH) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$228.47

Change

+0.57%

Market Cap

$54.28B

Avg Volume

2.1M

Company Overview

Cardinal Health, Inc. supplies a wide array of healthcare products and services, primarily focused on medical distribution. Headquartered in Dublin, Ohio, the company operates mainly in two segments: Pharmaceutical and Specialty Solutions, along with Global Medical Products and Distribution. Its customers include hospitals, pharmacies, ambulatory surgery centers, and home healthcare patients. Cardinal Health provides everything from branded and generic pharmaceuticals to medical supplies like surgical gloves, syringes, and wound care products.

As a major player in the healthcare distribution sector, Cardinal Health holds a strong competitive position, typically classified as a market leader. Its extensive distribution network and broad product offerings give it an edge over competitors such as McKesson Corporation and AmerisourceBergen. However, the company faces challenges, including rising competition from niche players and pricing pressures from healthcare providers pushing for cost reductions. Market dynamics are shifting toward value-based care, which could impact traditional revenue streams.

Currently, Cardinal Health is in a state of transition, with a focus on streamlining operations and improving profitability. The company has been proactive in addressing operational inefficiencies and restructuring to enhance its core business. Recent milestones include an increase in its specialty distribution services, which align with industry trends toward personalized medicine. This strategic pivot aims to capture higher margins and position Cardinal Health as a leader in the evolving healthcare landscape.

Key Financials

Market Cap

$54.28B

Revenue

$244.67B

EBITDA

$3.80B

Gross Margin

3.7%

Profit Margin

0.7%

Revenue Growth

18.8%

Total Cash

$2.78B

Total Debt

$9.03B

Free Cash Flow

$5.43B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

32.87

Forward P/E

19.59

Beta

N/A

52-Week High

$230.81

52-Week Low

$120.72

EPS

$6.95

50-Day Avg

$206.94

200-Day Avg

$171.63

Price/Book

-19.97

Technical Analysis

Over the past 52 weeks, Cardinal Health, Inc. (CAH) has demonstrated a strong upward trend, showing a remarkable 80.2% increase from its previous lows, suggesting robust investor confidence. Key support is observed around the $120 level established in February, while the recent resistance level appears to hover near $226.32, just below the current price of $228.47. Notable price patterns include a series of higher lows and a gradual rise, reflecting consistent buying pressure. In the last few weeks, momentum has picked up significantly as the price broke through previous resistance, indicating strong bullish sentiment. Currently, the stock is positioned at an all-time high relative to its 52-week range, suggesting a potentially overbought condition but also underscoring bullish market sentiment. This positioning indicates a strong demand for the stock, albeit with a need for caution regarding possible price corrections.

Recent News and Developments

Here’s a summary of the latest news and developments for Cardinal Health, Inc

(CAH) stock in the past week:

1. Strong Q2 Fiscal Year 2026 Earnings and Raised Full-Year Outlook

Cardinal Health announced robust financial results for its second quarter of fiscal year 2026 on February 5, 2026, surpassing analyst expectations. The company reported a 19% increase in revenue, reaching $65.6 billion, and a 29% rise in GAAP operating earnings to $707 million. Non-GAAP diluted earnings per share (EPS) grew by 36% to $2.63, exceeding the consensus estimate by 10.5%. Following this strong performance, Cardinal Health also raised its fiscal year 2026 non-GAAP EPS guidance to a range of $10.15 to $10.35, up from its previous outlook of at least $10.00.

2. Continued “Moderate Buy” Analyst Consensus and Price Target Updates

Analysts generally maintain a positive outlook on Cardinal Health, with a consensus rating of “Moderate Buy” from 16 firms. The average 12-month price target among brokerages is around $224.73. While no specific upgrades or downgrades were reported in the last week of February, recent analyst activity in January saw firms like Morgan Stanley, Wells Fargo, and Citigroup raising their price targets, indicating increasing confidence in the stock. Morgan Stanley, for instance, set a price target of $245.00 on January 29, 2026.

Market Sentiment and Analyst Recommendations

Bull Case

Cardinal Health just delivered a 19% revenue beat with 29% operating earnings growth in Q2 — that’s the kind of operational leverage that justifies the stock’s move. The 36% EPS growth to $2.63 blew past consensus by 10.5%, and management raised full-year guidance to $10.15-$10.35, signaling confidence in sustained momentum. The at-Home Solutions business is expanding with new programs like ContinuCare Pathway, tapping into the growing diabetes management market where margins are strong. At a P/E of 32.87, the valuation looks steep until you factor in the 18.8% revenue growth rate and the fact that 15 analysts rate this a strong buy with an average target of $242.40 — only 6% above current price. The company navigated the 2026 Medicare Drug Price Negotiation Program without stumbling, proving management can adapt to regulatory headwinds. With $2.78B in cash and an 80.2% gain from 52-week lows, the stock has real momentum and institutional backing.

Bear Case

A 32.87 P/E multiple is aggressive for a healthcare distributor, even with growth factored in. The stock is sitting at an all-time high with an 80% run-up in 52 weeks — that’s a lot of good news already priced in, and the chart analysis itself flags an overbought condition. Cardinal Health carries $9.03B in debt against $2.78B in cash, a 3.2x ratio that limits financial flexibility if margins compress or the economy weakens. Pharmaceutical distribution is structurally challenged by price pressure from payers and manufacturers, and the 2026 Medicare negotiation program will continue squeezing margins across the industry. The stock broke through resistance at $226.32 and is now extended, meaning a 10-15% pullback to $195-$205 would be normal and painful for recent buyers. Analyst targets range from $200 to $270 — that $70 spread suggests real disagreement about fair value.

What to Watch

Monitor Q3 and Q4 fiscal 2026 earnings closely to see if the 29% operating earnings growth was a beat or a new baseline. Watch for any margin compression in the pharmaceutical distribution segment as the Medicare negotiation program impacts pricing through the year — this is the biggest risk to the bull thesis. Track the at-Home Solutions revenue growth rate specifically; if ContinuCare Pathway adoption is slow or margins disappoint, that growth story falters. The company guides to $10.15-$10.35 EPS for full year 2026 — beat that by more than 5% and the stock justifies $250+; miss by more than 5% and you’re looking at a 15-20% correction. Watch the debt-to-cash ratio; if leverage tightens above 3.5x or the company can’t reduce debt meaningfully, that’s a red flag. Finally, pay attention to analyst downgrades from the major firms that recently raised targets — if Morgan Stanley or Wells Fargo reverse course, that’s a sign institutional confidence is cracking.

Analyst Consensus

STRONG BUY

Based on 15 analyst opinions

Low Target

$200.00

Mean Target

$242.40

High Target

$270.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Distribution

Employees

53,084

Earnings & Dividends

Next Earnings

Feb 05, 2026

EPS (Trailing)

$6.95

Dividend Yield

90.0%

Payout Ratio

29.3%

Frequently Asked Questions

Is CAH a good stock to buy?

Cardinal Health, Inc. (CAH) has a current price of $228.47 and a strong market cap of $54.28 billion. Analysts rate it a STRONG BUY with a target price of $242.40, indicating significant upside potential.

What is CAH’s price target?

The current analyst consensus for Cardinal Health is a price target of $242.40. Given the stock is trading at $228.47, this represents an approximate upside of 6.1%.

Does CAH pay a dividend?

Yes, Cardinal Health has a substantial dividend yield of 90.0%. This makes it attractive for income-focused investors.

What is CAH’s P/E ratio?

Cardinal Health has a P/E ratio of 32.87 and a forward P/E of 19.59. This suggests that while the stock is currently valued high, its future earnings could justify the current price.

What has been CAH’s stock performance over the past year?

Cardinal Health’s stock has traded between $120.72 and $230.81 over the past year. The current price is closer to the high end of this range, indicating strong performance.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.